Phage based therapies for Brucellosis in cattle to mitigate antimicrobial resistance

  05 March 2024

Researchers have isolated Brucellaphage Ludhiana (BpL) and used it for phage-based therapies of Brucellosis in cattle. They found that phage therapy initially stimulates immune responses, which decline slowly after 45 days. Live attenuated B. abortus vaccine strain S19 organisms were used to deliver a lytic Brucellaphage, causing high titers of anti-Brucella antibodies. The study also demonstrated the successful therapy of bovine Brucellosis using phage lysates of RB51 and S19.

 

Further reading: Research Gate
Author(s): Hari Mohan Saxena et al
Healthy Animals  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Your Biweekly Source for Global AMR Insights!

Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.

Don’t miss out on staying ahead in the global AMR movement—subscribe now!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed